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without chronic GVHD was 97% and 76%, respectively
(p¼0.002). The cumulative incidence of squamous cell
carcinoma (SCC) at 10yswas 8% and at 15yswas 14%. SCC was
more common in those who reported chronic GVHD
compared to those without chronic GVHD (14% vs. 4%,
p¼0.03). Endocrine dysfunction was common with
hypogonadism in 40% of patients and hypothyroidism in 25%.
Normal pregnancies occurred in 4 females with normal
offspring. Neurological, auditory, visual, pulmonary, hepatic
and renal complications were disease-related or transplant
procedure but occurred at substantially lower frequencies.
There were 20 deaths (13%) that occurred after 2 years. SCC
was the predominant cause of death (n¼8). Other causes of
death include, chronic GVHD (n¼6), rejection (n¼2),
pulmonary complications (n¼2), urinary sepsis (n¼1) and
hepatitis C (n¼1). In summary, most long-term survivors are
disease-free and lead functional lives. However, for those
patients with late complications of transplantation or its
effects, efforts must be directed at lowering morbidity and
mortality.62
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Allogeneic hematopoietic cell transplantation (allo HCT)
survivors are at risk for long-term mortality from late
complications. Low socioeconomic status (SES) has been
shown to be associated with health care disparities including
poor access and adverse outcomes in a variety of health
conditions. Early post-transplant care is typically well
coordinated through the patients transplant center.
However, as patients transition back to their community
providers, it is possible that patients with less resources and
poor access to healthcare would be at higher risk for
complications and mortality. Hence, we hypothesized that
SES would be associated with survival and non-relapseFigure. Overall survival by SES in 1 year allogeneic HCT survivorsmortality (NRM) in long-term survivors after allo HCT. We
studied 283 consecutive allo HCT recipients transplanted
between 2003 and 2012 who had survived for at least 1 year
in remission. Median annual household income was
estimated using Census tract data and from ZIP code of
residence at the time of transplant. SES categories were
determined by recursive partitioning analysis and were
categorized into low SES (<$51,000/yr, N¼203) and high SES
($51,000/yr, N¼80). Low SES patients were more likely to
be of non-White race (10% vs. 1%), otherwise there were no
notable differences between the two cohorts, including
diagnosis, disease status, HCT-Comorbidity Index scores,
donor source, graft source and conditioning regimen
intensity. In univariate analysis, low SES patients had
signiﬁcantly worse survival (Figure) and NRM but
comparable incidence of relapse mortality. In multivariate
analyses that adjusted for patient, disease and transplant
characteristics, patients with low SES had signiﬁcantly
higher risks of all-cause mortality (HR 1.98, 95% CI 1.16-3.37,
p¼0.012) and NRM (HR 2.22, 95% CI 1.09-4.50, p¼0.028), but
similar risks of relapse mortality (HR 1.01, 95% CI 0.44-2.34,
p¼0.97) compared to high SES patients. Common causes of
death in low SES and high SES patients included disease
relapse (39% vs 47%), infections (20% vs 12%), organ toxicity
(17% vs 18%) and chronic graft-versus-host disease (11% vs
18%). In conclusion, 1 year allo HCT survivors with low SES
have inferior overall survival that is driven by higher NRM
compared to patients with high SES. More research is needed
to understand the reasons for these health care disparities
and identify interventions to mitigate them.63
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Background: Venous Thromboembolism (VTE) is a common
late effect after Hematopoietic Stem Cell Transplant with
wide variation in reported frequency of incidence (1-20% of
patients). There is lack of data with respect to risks and
outcomes of VTE, unlike sinusoidal obstruction syndromes
(SOS) for which adequate literature is available. Therefore,
optimal approach for prevention and management of VTE in
HSCT patients is unknown. We sought to conduct a
meta-analysis of VTE incidence and evaluate its risk factors in
HSCT patients.
Methods: A comprehensive search of several databases from
each database’s earliest inception to June 2, 2014 in any
language was conducted by an experienced medical
librarian. The databases included Ovid Medline In-Process &
Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE,
Ovid CCT and Scopus. To avoid publication bias, we also
searched annual meeting abstracts from ASBMT, EBMT, ASH,
SIOP, and ISTH. The electronic search generated 755 articles.
Only 34 studies met the strict selection criteria. Case reports,
review articles, meta-analysis, postmortem reports, and
solid organ transplants were excluded. Two investigators
independently analyzed the studies for ﬁnal selection. Both
autologous and allogeneic HSCTs were included for any
